|
|
|
|
LEADER |
05835nam a2200673 4500 |
001 |
ocn905802006 |
003 |
OCoLC |
005 |
20170124070738.2 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
150327s2015 nju ob 001 0 eng |
010 |
|
|
|a 2015012590
|
040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d YDX
|d OCLCF
|d N$T
|d IDEBK
|d YDXCP
|d EBLCP
|d CDX
|d DG1
|d COO
|d DEBBG
|d KSU
|d GrThAP
|
020 |
|
|
|a 9781118846193
|q electronic bk.
|
020 |
|
|
|a 1118846192
|q electronic bk.
|
020 |
|
|
|z 9781118846209
|
020 |
|
|
|z 1118846206
|
020 |
|
|
|z 9781118846216
|
020 |
|
|
|z 1118846214
|
020 |
|
|
|z 9781119971399 (cloth)
|
020 |
|
|
|a 111997139X (cloth)
|
020 |
|
|
|a 9781119971399 (cloth)
|
029 |
1 |
|
|a DEBBG
|b BV043737977
|
035 |
|
|
|a (OCoLC)905802006
|
042 |
|
|
|a pcc
|
050 |
0 |
0 |
|a QH588.S83
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
0 |
|a 616.02/774
|2 23
|
049 |
|
|
|a MAIN
|
245 |
0 |
0 |
|a Stem cells in regenerative medicine :
|b science, regulation and business strategies /
|c edited by Alain Vertes, Nasib Qureshi, Arnold Caplan, Lee Babiss.
|
264 |
|
1 |
|a Hoboken, NJ :
|b John Wiley & Sons, Ltd,
|c 2015.
|
300 |
|
|
|a 1 online resource.
|
336 |
|
|
|a text
|2 rdacontent
|
337 |
|
|
|a computer
|2 rdamedia
|
338 |
|
|
|a online resource
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Therapeutic stem cells answer a strategic breakthrough need of healthcare / Alain Vertes -- Ethical considerations on the research and business of stem cells / Ljiljana Minwalla -- Projected growth of the worldwide stem cell market / Ed Field -- Cell therapy manufacturing: identifying and meeting demand / Jessica Carmen, David A. Brindley, Natasha L. Davie and David Smith -- The history of stem cell transplantation / Hilliard M. Lazarus and Stan Gerson -- Regulatory and intellectual property considerations for therapeutic human stem cell-based regenerative medicine product development: a U.S. perspective / Michael Mendicino and Darin Weber -- The regulation of stem cells in the UK and EU / Alex Denoon, Julian Hitchcock and James Lawford Davies -- The business of stem cell research tools / Erik Miljan -- Stem cell-derived cardiomyocytes and hepatocytes as tools for drug development and screening applications / Kate Camerona, Howard Marriage, David Haya and Claire Medine -- Stem cell tools for compound development / Tom Novak -- Stem cell origin of cancer: prospects for functional therapeutics and regenerative medicine / Vinagolu K. Rajasekhar -- The market of stem cell medicines for domestic and high value animals / Bob J. Harmann -- Stem cells veterinary medicines: a conceptual approach / John Peroni and Lindsey Boone -- Stem cells in veterinary medicines: a practical approach / Bob J. Harmann -- Stem cell veterinary medicines as success signals towards human stem cell therapeutics / Alain Vertes -- Animal models in regenerative medicine / Andrew N. Bubak, John D. Elsworth and John R. Sladek, Jr. -- Stem cell characterization: a guide to stem cell types, technologies, and future applications / Justin Lo Re, Rezma Shrestha and Leonard Sciorra -- Stem cell value chains / Judy Muller-Cohn, Paul Diaz and Rolf Muller -- Stem cell culture processes / Ravali Raju, Shikha Sharma and Wei-Shou Hu -- Indication transformation maps and the challenge of live cells delivery / Bob Deans and Lee Babiss -- Delivery and targeting of therapeutic cells / Paul Lin, Arnold I. Caplan and Erkki Ruoshlati -- Hematopoietic stem cells / Steve Wolpe and Lynnet Koh -- MSCs: the new medicince / Arnold Caplan -- Innovation and commercialization of induced pluripotent stem cells / Shintaro Sengoku -- Embryonic stem cells / Rachel Eiges, Benjamin E. Reubinoff and Charles Irving -- Allogeneic versus autologous stem cell transplantation in regenerative medicine / Kathy Trzaska-Accurso and Pranela Rameshwar -- Clinical immunological barriers to regenerative medicine: do they matter? / Cristina Trento and Francesco Dazzi -- Challenges in the clinical development of stem cells / John Caulfield -- Pricing and reimbursement of regenerative medicines / Nathan Dowden -- The role of patient advocacy in the clinical translation of regenerative medicine / Bernard Siegel and Alan Jakimo -- Financing strategies for regenerative medicine start-ups / Carol Julie Walton, Lee Buckler and Gregory A. Bonfiglio -- Strategic alliances, mergers and acquisitions in regenerative medicine / Nafees N. Malik, Timothy E. Allsopp and Devyn M. Smith -- History of monoclonal antibodies and lessons for the development of stem cell therapeutics / Alain Vertes and Nathan Dowden -- Deployment of stem cell technologies in industry and healthcare/ Alain Vertes.
|
588 |
|
|
|a Description based on print version record and CIP data provided by publisher.
|
650 |
|
0 |
|a Stem cells.
|
650 |
|
0 |
|a Regenerative medicine.
|
650 |
|
7 |
|a Regenerative medicine.
|2 fast
|0 (OCoLC)fst01745494
|
650 |
|
7 |
|a Stem cells.
|2 fast
|0 (OCoLC)fst01132975
|
650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL / Clinical Medicine
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
655 |
|
4 |
|a Electronic books.
|
700 |
1 |
|
|a Vertes, Alain A.,
|e editor.
|
700 |
1 |
|
|a Qureshi, Nasib,
|e editor.
|
700 |
1 |
|
|a Caplan, Arnold I.,
|e editor.
|
700 |
1 |
|
|a Babiss, Lee Edward,
|d 1956-
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Stem cells in regenerative medicine
|d Hoboken, NJ : John Wiley & Sons, Ltd, 2015
|z 9781119971399
|w (DLC) 2015007931
|
856 |
4 |
0 |
|u https://doi.org/10.1002/9781118846193
|z Full Text via HEAL-Link
|
994 |
|
|
|a 92
|b DG1
|